Study to Investigate the Performance of Cervical Arthroplasty for the Treatment of Cervical Degenerative Disc Disease

Cervical Degenerative Disc Disease Clinical Trial

Official title:

A Multi-Centre, Prospective, Randomized, Post Marketing Surveillance Study Comparing Cervical Arthroplasty to Anterior Cervical Discectomy and Fusion (ACDF) for the Treatment of Cervical Degenerative Disc Disease

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT00700739
• Other study ID #: CT 05/25
• Status: Terminated
• Phase: Phase 4
• First received: June 18, 2008
• Last updated: September 2, 2015
• Start date: May 2008
• Est. completion date: May 2010

Study information

• Verified date: September 2015
• Source: DePuy International
• Contact: n/a
• Is FDA regulated: No
• Health authority: Germany: Federal Institute for Drugs and Medical Devices
• Study type: Interventional

Clinical Trial Summary

The purpose of the study is to evaluate the performance of the Discover cervical Artificial disc in the treatment of degenerative disc disease in one level of the cervical spine.

Description:

The protocol underwent 3 amendments, the last of which (02APR2009) changed the study design from a randomized to a non-randomized and non-comparative clinical trial. All of the subjects were enrolled under the randomized design with the exception of the last subject. This study is not applicable per FDAA Title VIII, Section 801 due to the final trial design. However, results are submitted to clinicaltrials.gov due to the majority of study data being collected under a randomized (FDAA Title VIII, Section 801 applicable) trial design

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 60
• Est. completion date: May 2010
• Est. primary completion date: May 2010
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

• Male or female subjects, aged between 18 and 65 years inclusive.

• Subjects who are able to give voluntary, written informed consent to participate in this clinical investigation and from whom consent has been obtained.

• Subjects who, in the opinion of the Clinical Investigator, are able to understand this clinical investigation, co-operate with the investigational procedures and are willing to return to the hospital for all the required post-operative follow-ups.

• Objective evidence of cervical disc disease in one vertebral level between C3-C7 defined as one or more of the following:

• Shoulder and/or arm pain in a radicular distribution resulting from herniated disc or bony osteophytes (Consistent w diagnostic imaging including Axial CT, CT Myelogram, MRI and/or plain films)

• Subjects with myeloradiculopathy resulting from mild spinal cord compression and nerve root impingement

• Unresponsive to documented non-surgical management for = 6 weeks and/or presents with progressive symptoms of nerve root or spinal cord compression in the face of continued non-surgical management (e.g., physical therapy, medication therapy, corticosteroid injections, etc.)

• Minimum Neck Disability Index score of =30 % (15/50 points)

Exclusion Criteria:

• Subjects who, in the opinion of the Clinical Investigator, have an existing condition that would compromise their participation and follow-up in this clinical investigation.

• Subjects who are pregnant, lactating or wishes to become pregnant within the duration of the study.

• Subjects who are known drug or alcohol abusers or with psychological disorders that could affect follow-up care or treatment outcomes.

• Subjects who have participated in a clinical investigation with an investigational product in the last 30 days.

• Subjects who are currently involved in any injury litigation claims.

• Subjects with significant degeneration at more than one cervical level (e.g. DISH, ankylosing spondylitis, congenital abnormality, rheumatoid arthritis)

• Subjects who have had any prior surgery at the level to be treated (subjects with a prior Laminotomy at the level to be treated may be included in the study)

• Subjects who have marked cervical instability on lateral or flexion/extension x-rays defined as translation =3mm and/or =11 degrees of rotational difference to either adjacent level

• Subjects who have presence of systemic infection or infection at the site of surgery

• Subjects who have been diagnosed with malignancy

• Subjects who have been diagnosed with a condition or require postoperative medication(s) that may interfere with bony/soft tissue healing

• Subjects who have been diagnosed with Osteoporosis, Osteopenia, other metabolic bone disease or endocrine disorder known to affect osteogenesis.

• Subjects with pre-existing neurological abnormalities other than deficits produced from the spinal lesion (e.g., MS, Parkinson's, CVA, diabetic neuropathy, peripheral neuropathy).

• Subjects with morbid obesity defined as a BMI of =40, or more than 100 lbs (45.4kg) over ideal weight.

• Subjects with any known allergy to titanium metal, polyethylene, metal alloy or carbon fibre reinforced polymer

• Subjects who have had prior fusion surgery at any level(s) (C1-T1)

• Subjects with kyphosis >-15 degrees evaluated using the Cobb angle measurement

• Subjects with Significant cervical degenerative disease characterized by bridging anterior osteophytes, significant loss of disc space height (3mm or less), sclerotic facets, large posterior osteophytes, autofusion of other cervical levels, and degenerative retrolisthesis. Spinal diseases such as DISH, ankylosing spondylitis, congenital abnormality, and rheumatoid arthritis, should also be excluded

• Subjects undergoing treatment with a bone growth stimulator, which cannot be discontinued prior to enrollment in the study.

• Significant kyphotic deformity or significant reversal of lordosis.

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Cervical Degenerative Disc Disease
• Intervertebral Disc Degeneration
• Spinal Diseases

Intervention

Device:
• DISCOVER™ Artificial Cervical Disc
DISCOVER™ Artificial Cervical Disc
• ACDF
Cervical CFRP I/F CAGE® and SLIM LOC(R) Anterior Cervical Plate System with allograft

Locations

Country	Name	City	State
Australia	Westmead Private Hospital	Sydney	New South Wales
Australia	Calvary Hospital	Tasmania
Germany	Klinikum Neustadt	Neustadt	Holstein
Italy	Divisione di Neurochirurgia	Rome
Malaysia	Island Hospital	Penang
Netherlands	Elisabeth Ziekenhuis	Tilburg
Spain	La Paz Hospital	Madrid
United Kingdom	Hope Hospital	Manchester	Lancashire

Sponsors (1)

Lead Sponsor	Collaborator
DePuy International

Countries where clinical trial is conducted

Australia,  Germany,  Italy,  Malaysia,  Netherlands,  Spain,  United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Overall Patient Success	Overall success was a composite endpoint determined by the following clinical outcome measures: 1. Neck Disability Index = 15-point improvement from baseline to 12 months post-operative, 2. No new clinically significant permanent abnormalities in neurological function (i.e. motor strength, nerve root tension signs, sensory and reflex signs) from baseline to 12 months post-operative, 3. No subsequent secondary surgical interventions (SSI) at the index level, and 4. No device-related serious events (dSAE) from intra-operative through 12-months post-operative. Please note that these time periods were intended to be from baseline to 24 months post-operative, but since the study was terminated early the 12 month time periods were utilized.	12 months	Yes
Secondary	Change in Visual Analogue Scale (VAS) Neck Pain From Pre-treatment to 12 Months	The visual analogue scale (VAS) pain score asks the subject to place a vertical mark on a horizontal line (that is approximately 10 cm long) with 'No Pain' (score of 0 = 0 cm) listed on the left and 'Very severe pain' (score of 100 = 10 cm) labeled on the right. The subject is instructed to indicate the amount of pain they feel in their neck.	12 months	No
Secondary	Change in Visual Analogue Scale (VAS) Left Arm Pain From Pre-treatment to 12 Months.	The visual analogue scale (VAS) pain score asks the subject to place a vertical mark on a horizontal line (that is approximately 10 cm long) with 'No Pain' (score of 0 = 0 cm) listed on the left and 'Very severe pain' (score of 100 = 10 cm) labeled on the right. The subject is instructed to indicate the amount of pain they feel in their left arm.	12 Months	No
Secondary	Change in Visual Analogue Scale (VAS) Right Arm Pain From Pre-treatment to 12 Months.	The visual analogue scale (VAS) pain score asks the subject to place a vertical mark on a horizontal line (that is approximately 10 cm long) with 'No Pain' (score of 0= 0 cm) listed on the left and 'Very severe pain' (score of 100= 10 cm) labeled on the right. The subject is instructed to indicate the amount of pain they feel in their right arm.	12 Months	No
Secondary	Change in Visual Analogue Scale (VAS) Right Shoulder Pain From Pre-treatment to 12 Months.	The visual analogue scale (VAS) pain score asks the subject to place a vertical mark on a horizontal line (that is approximately 10 cm long) with 'No Pain' (score of 0 = 0 cm) listed on the left and 'Very severe pain' (score of 100 = 10 cm) labeled on the right. The subject is instructed to indicate the amount of pain they feel in their right shoulder.	12 Months	No
Secondary	Change in Visual Analogue Scale (VAS) Left Shoulder Pain From Pre-treatment to 12 Months.	The visual analogue scale (VAS) pain score asks the subject to place a vertical mark on a horizontal line (that is approximately 10 cm long) with 'No Pain' (score of 0 = 0 cm) listed on the left and 'Very severe pain' (score of 10 = 10 cm) labeled on the right. The subject is instructed to indicate the amount of pain they feel in their left shoulder.	12 Months	No
Secondary	Change in Mental Component Summary Quality of Life Measure Assessed by Short Form SF-36 From Pre-treatment to 12 Months	The 36-item Short Form Health Survey (SF-36) is a patient reported outcome survey that evaluates functional health and well-being. The survey is converted into 2 summary measures that are scored from 0 to 100 (where 100 indicates the highest level of health) - the Physical Component Score (PCS-36) and Mental Component Score (MCS-36)	12 months	No
Secondary	Change in Physical Component Summary Quality of Life Measure Assessed by Short Form SF-36 From Pre-treatment to 12 Months	The 36-item Short Form Health Survey (SF-36) is a patient reported outcome survey that evaluates functional health and well-being. The survey is converted into 2 summary measures that are scored from 0 to 100 (where 100 indicates the highest level of health) - the Physical Component Score (PCS-36) and Mental Component Score (MCS-36)	12 months	No
Secondary	Change in Function Assessed by Neck Disability Index Improvement From Pre-treatment to 12 Months	The neck disability index (NDI) is a validated, disease specific, self-administrated questionnaire for assessing pain intensity and function in patients with neck pain on a scale from 0 to 100. A lower score is a better result (i.e. less severe pain and/or better function). The proportion of patients with an improved score (lower) of 15 points or more was the analysis variable.	12 months	No
Secondary	Work Status Assessed at 12 Months	The proportion of subjects with unrestricted work status (compared to subjects not working or with restricted work status) is reported at the 12 month follow-up interval.	12 months	No
Secondary	Sagittal Angulation, Also Known as Global Lordosis, Measured Radiographically at 6 Months	Sagittal Angulation is a measure of the angle formed between the inferior endplate of the C2 vertebrae and the corresponding inferior endplate of vertebrae C7 of the spine, measured in degrees, from a side (sagittal) view.	6 months	No
Secondary	Adjacent Level Degeneration Measured Radiographically at 24 Months	Adjacent Level Degeneration is evaluated using a point system that assigns numerical scores to severity of Height Loss, Anterior Osteophytes, and Endplate Sclerosis; and then grades into one of the following five categories: None, Mild, Moderate, Severe, or NA.	24 months	No
Secondary	Maintenance of Disc Height Measured Radiographically at 6 Months	Maintenance of disc height is measured at the index and adjacent levels to determine the effect of the treatment on restoration or maintenance of the disc height. Initial post-operative disc height is compared with subsequent post-operative visits (i.e. 6 months) to evaluate the maintenance of disc height. The height is measured in millimeters (mm).	6 months	No
Secondary	Foraminal Height Measured Radiographically at 24 Months	Foraminal height is the maximum vertical distance, measured in millimeters (mm), between the inferior surface of the superior pedicle and superior surface of the inferior pedicle. These measurements are obtained via magnetic resonance imaging (MRI).	24 months	No
Secondary	Cervical Range of Motion Measured Radiographically at 6 Months	Cervical range of motion measures the angle, in degrees, between the inferior endplate of C2 to the inferior endplate of C7 on flexion-extension radiographs.	6 months	No
Secondary	Device Related Adverse Events	The proportion of subjects with device related adverse events as reported throughout the duration of the study.	Intra-operatively to 24 months post-operative	Yes